Tracing the variation in physiological response to rifampicin across the microbial spectrum

Journal of Bacteriology and Virology

Volumn 42, Issue 2, 2012, Pages 87-100

  Chatterji, Dipankar ^a   Dey, Abhinav ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

Antibiotic resistance; Rifampicin; RNA polymerase

Indexed keywords

EID: 84922685609     PISSN: 15982467     EISSN: None     Source Type: Journal    
DOI: 10.4167/jbv.2012.42.2.87     Document Type: Review

References (58)

1. Darst S.A. New inhibitors targeting bacterial RNA poly-merase. Trends Biochem Sci 2004;29:159-160.
2. Quan S, Venter H, Dabbs E.R. Ribosylative inactivation of rifampin by Mycobacterium smegmatis is a principal contributor to its low susceptibility to this antibiotic. Antimicrob Agents Chemother 1997;41:2456-2460.
3. Hu Y, Mangan J.A., Dhillon J, Sole K.M., Mitchison D.A., Butcher P.D., et al. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol 2000;182:6358-6365.
4. 32-dependent promoters by rifampicin. FEBS Lett 1998;440:172-174.
5. Newell KV, Thomas DP, Brekasis D, Paget MS. The RNA polymerase-binding protein RbpA confers basal levels of rifampicin resistance on Streptomyces coelicolor. Mol Microbiol 2006;60:687-696.
6. Flåtten I, Morigen, Skarstad K. DnaA protein interacts with RNA polymerase and partially protects it from the effect of rifampicin. Mol Microbiol 2009;71:1018-1030.
7. Martinez JL. Antibiotics and antibiotic resistance genes in natural environments. Science 2008;321:365-367.
8. Oppolzer W, Prelog V, Sensi P. The composition of rifamycin B and related rifamycins. Experientia 1964; 20:336-339.
9. Hinkle DC, Mangel WF, Chamberlin MJ. Studies of the binding of Escherichia coli RNA polymerase to DNA. I V. The effect of rifampicin on binding and on RNA chain initiation. J Mol Biol 1972;70:209-220.
10. Yarbrough LR, Wu FY, Wu CW. Molecular mechanism of the rifampicin -RNA polymerase interaction. Biochemistry 1976;15:2669-2676.
11. McClure WR, Cech CL. On the mechanism of rifampicin inhibition of RNA synthesis. J Biol Chem 1978;253:8949-8956.
12. Jin DJ, Gross CA. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J Mol Biol 1988;202:45-58.
13. Campbell EA, Korzheva N, Mustaev A, Murakami K, Nair S, Goldfarb A, et al. Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell 2001;104:901-912.
14. Korzheva N, Mustaev A, Kozlov M, Malhotra A, Nikiforov V, Goldfarb A, et al. A structural model of transcription elongation. Science 2000;289:619-625.
15. Thornsberry C, Hill BC, Swenson JM, McDougal LK. Rifampin: Spectrum of antibacterial activity. Rev Infect Dis 1983;5:S412-S417.
16. Williams KJ, Piddock LJ. Accumulation of rifampicin by Escherichia coli and Staphylococcus aureus. J Antimicrob Chemother 1998;42:597-603.
17. Hui J, Gordon N, Kajioka R. Permeability barrier to rifampin in mycobacteria. Antimicrob Agents Chemother 1977;11:773-779.
18. Siddiqi N, Das R, Pathak N, Banerjee S, Ahmed N, Katoch VM, et al. Mycobacterium tuberculosis isolate with a distinct genomic identity overexpresses a taplike efflux pump. Infection 2004;32:109-111.
19. Hagman KE, Pan W, Spratt BG, Balthazar JT, Judd RC, Shafer WM. Resistance of Neisseria gonorrhoeae to antimicrobial hydrophobic agents is modulated by the mtrRCDE efflux system. Microbiology 1995;141:611-622.
20. Imai T, Watanabe K, Mikami Y, Yazawa K, Ando A, Nagata Y, et al. Identification and characterization of a new intermediate in the ribosylative inactivation pathway of rifampin by Mycobacterium smegmatis. Microb Drug Resist 1999;5:259-264.
21. Dabbs ER, Yazawa K, Tanaka Y, Mikami Y, Miyaji M, Andersen SJ, et al. Rifampicin inactivation by Bacillus species. J Antibiot 1995;48:815-819.
22. Tanaka Y, Yazawa K, Dabbs ER, Nishikawa K, Komaki H, Mikami Y, et al. Different rifampicin inactivation mechanisms in Nocardia and related taxa. Microbiol Immunol 1996;40:1-4.
23. Ishikawa J, Yamashita A, Mikami Y, Hoshino Y, Kurita H, Hotta K, et al. The complete genome sequence of Nocardia farcinica IFM 10152. Proc Natl Acad Sci U S A 2004;101:14925-14930.
24. Talà A, Wang G, Zemanova M, Okamoto S, Ochi K, Alifano P. Activation of dormant bacterial genes by Nonomuraea sp. strain ATCC 39727 mutant-type RNA polymerase. J Bacteriol 2009;191:805-814.
25. Kühner S, van Noort V, Betts MJ, Leo-Macias A, Batisse C, Rode M, et al. Proteome organization in a genome-reduced bacterium. Science 2009;326:1235-1240.
26. Mukherjee R, Chatterji D. Stationary phase induced alterations in mycobacterial RNA polymerase assembly: A cue to its phenotypic resistnce towards rifampicin. Biochem Biophys Res Commun 2008;369:899-904.
27. Dey A, Verma AK, Chatterji D. Role of an RNA polymerase interacting protein, MsRbpA, from Mycobacterium smegmatis in phenotypic tolerance to rifampicin. Microbiology 2010;156:873-883.
28. Dey A, Verma AK, Chatterji D. Molecular insights into the mechanism of phenotypic tolerance to rifampicin conferred on mycobacterial RNA polymerase by MsRbpA. Microbiology 2011;157:2056-2071.
29. Liu A, Tran L, Becket E, Lee K, Chinn L, Park E, et al. Antibiotic sensitivity profiles determined with an Escherichia coli gene knockout collection: Generating an antibiotic bar code. Antimicrob Agents Chemother 2010;54:1393-1403.
30. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M, et al. Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol 2006;2:2006.0008.
31. Ren H, Liu J. AsnB is involved in natural resistance of Mycobacterium smegmatis to multiple drugs. Antimicrob Agents Chemother 2006;50:250-255.
32. Ojha A, Anand M, Bhatt A, Kremer L, Jacobs WR, Hatfull GF. GroEL1: a dedicated chaperone involved in mycolic acid biosynthesis during biofilm formation in mycobateria. Cell 2005;123:861-873.
33. Kovacs L, Csanadi A, Megyeri K, Kaberdin VR, Miczak A. Mycobacterial RNase E-associated proteins. Microbiol Immunol 2005;49:1003-1007.
34. Macinga DR, Rather PN. aarD, a Providencia stuartii homologue of cydD: role in 2'-N-acetyltransferase expression, cell morphology and growth in the presence of an extracellular factor. Mol Microbiol 1996;19:511-520.
35. Handschin JC, Wehrli W. On the kinetics of the rifampicin-RNA-polymerase complex. Differences between crude and purified enzyme fractions. Eur J Biochem 1976;66:309-317.
36. Kumar KP, Reddy PS, Chatterji D. Proximity relationship between the active site of Escherichia coli RNA polymerase and rifampicin binding domain: A resonance energy-transfer study. Biochemistry 1992;31:7519-7526.
37. Harshey RM, Ramakrishnan T. Purification and properties of DNA -dependent RNA polymerase from Mycobacterium tuberculosis H37RV. Biochim Biophys Acta 1976;432:49-59.
38. Fábry M, Sümegi J, Venetianer P. Purification and properties of the RNA polymerase of an extremely thermophilic bacterium: Thermus aquaticus T2. Biochim Biophys Acta 1976;435:228-235.
39. Zenkin N, Kulbachinskiy A, Bass I, Nikiforov V. Different rifampin sensitivities of Escherichia coli and Mycobacterium tuberculosis RNA polymerases are not explained by the difference in the β-subunit rifampin regions I and II. Antimicrob Agents Chemother 2005; 49:1587-1590.
40. Ishikawa J, Yamashita A, Mikami Y, Hoshino Y, Kurita H, Hotta K, et al. The complete genome sequence of Nocardia farcinica IFM 10152. Proc Natl Acad Sci U S A 2004;101:14925-14930.
41. Vigliotta G, Tredici SM, Damiano F, Montinaro MR, Pulimeno R, di Summa R, et al. Natural merodiploidy involving duplicated rpoB alleles affects secondary metabolism in producer actinomycete. Mol Microbiol 2005;55:396-412.
42. Ishikawa J, Chiba K, Kurita H, Satoh H. Contribution of rpoB2 RNA polymerase β-subunit gene to rifampin resistance in Nocardia species. Antimicrob Agents Chemother 2006;50:1342-1346.
43. Zhou YN, Jin DJ. The rpoB mutants destabilizing initiation complexes at stringently controlled promoters behave like stringent RNA polymerases in Escherichia coli. Proc Natl Acad Sci U S A 1998;95:2908-2913.
44. B-dependent general and multiple stress response. J Bacteriol 2002;184:459-467.
45. Aldridge BB, Fernandez-Suarez M, Heller D, Ambravaneswaran V, Irimia D, Toner M, et al. Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility. Science 2012;335:100-104.
46. Davies J, Spiegelman GB, Yim G. The world of sub-inhibitory antibiotic concentrations. Curr Opin Microbiol 2006;9:445-453.
47. Goh EB, Yim G, Tsui W, McClure J, Surette MG, Davies J. Transcriptional modulation of bacterial gene expression by subinhibitory concentrations of antibiotics. Proc Natl Acad Sci U S A 2002;99:17025-17030.
48. Piddock LJ, Williams KJ, Ricci V. Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. J Antimicrob Chemother 2000;45:159-165.
49. Dantas G, Sommer MO, Oluwasegun RD, Church GM. Bacteria subsisting on antibiotics. Science 2008;320: 100-103.
50. Davies J. Darwin and microbiomes. EMBO Rep 2009; 10:805.
51. Andersen SJ, Quan S, Gowan B, Dabbs ER. Monooxygenase-like sequence of a Rhodococcus equi gene conferring increased resistance torifampin by inactivating this antibiotic. Antimicrob Agents Chemother 1997;41:218-221.
52. Yazawa K, Mikami Y, Maeda A, Akao M, Morisaki N, Iwasaki S. Inactivation of rifampin by Nocardia brasiliensis. Antimicrob Agents Chemother 1993;37: 1313-1317.
53. Yazawa K, Mikami Y, Maeda A, Morisaki N, Iwasaki S. Phosphorylative inactivation of rifampicin by Nocardia otitidiscaviarum. J Antimicrob Chemother 1994;33: 1127-1135.
54. Li XZ, Zhang L, Nikaido H. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegmatis. Antimicrob Agents Chemother 2004;48:2415-2423.
55. Eng RH, Padberg FT, Smith SM, Tan EN, Cherubin CE. Bactericidal effects of antibiotics on slowly growing and nongrowing bacteria. Antimicrob Agents Chemother 1991;35:1824-1828.
56. Xie Z, Siddiqi N, Rubin EJ. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2005;49:4778-4780.
57. Perkins AE, Nicholson WL. Uncovering new metabolic capabilities of Bacillus subtilis using phenotype profiling of rifampin-resistant rpoB mutants. J Bacteriol 2008; 190:807-814.
58. Heep M, Odenbreit S, Beck D, Decker J, Prohaska E, Rieger U, et al. Mutations at four distinct regions of the rpoB gene can reduce the susceptibility of Helicobacter pylori to rifamycins. Antimicrob Agents Chemother 2000;44:1713-1715.